Comments on: Innovent Announces First Patient Dosed in Phase 1 Study of IBI3020, Global First-in-class Dual Payload CEACAM5 ADC, in Patients with Advanced Malignancies

Comments on: Innovent Announces First Patient Dosed in Phase 1 Study of IBI3020, Global First-in-class Dual Payload CEACAM5 ADC, in Patients with Advanced Malignancies https://9krapalm.com/innovent-announces-first-patient-dosed-in-phase-1-study-of-ibi3020-global-first-in-class-dual-payload-ceacam5-adc-in-patients-with-advanced-malignancies/ เสิร์ฟข่าวไอที อัปเดตเทคโนโลยีสไตล์ @krapalm Wed, 30 Apr 2025 00:27:12 +0000 hourly 1 https://wordpress.org/?v=7.0.1